Clinical Research Directory

Inclusion Criteria: * A willing participant who speaks French fluently, is willing to follow the protocol, is able to read and understand the informed consent form, and can give their free and informed consent; * Age between 18 and 35 years * Daily screen use of more than 4 hours * Monocular and binocular distance and near visual acuity of 0.1 logMAR or better (equivalent to 20/25 Snellen or 8/10) with best optical correction * Emmetropic groups: * Spherical equivalent (SE): -0.50 D \< SE ≤ +0.50 D * Regular astigmatism (cylinder) 0.75 D (absolute value) * Anisometropia 1.00 D * Myopic groups: * Spherical equivalent (SE): -5.00 D ≤ SE ≤ -0.50 D * Regular astigmatism (cylinder) 0.75 D (absolute value) * Anisometropia 1.50 D * Groups with signs and symptoms of DED: * OSDI-6 questionnaire score ≥ 4 * NIBUT \<10 seconds * Groups without signs and symptoms of DED: * OSDI-6 questionnaire score \< 4 * NIBUT ≥ 10 seconds. Exclusion Criteria: * Age \< 18 years * Pregnant or breastfeeding women * Individuals deprived of liberty by a judicial or administrative decision, and individuals hospitalized without consent under Articles L3212-1 and L3213-1 who do not fall under Article L1121-8, as well as individuals admitted to a healthcare or social institution for purposes other than research * Adults lacking legal capacity or unable to provide informed consent ; * Participants currently in the exclusion period of another research study; * All categories of individuals receiving special protection under French law are excluded from this research * Employees of Essilor International, Luxottica, GrandVision, or any of their subsidiaries. * Declared, untreated, and/or uncontrolled systemic disease that may affect vision (e.g., uncontrolled diabetes, uncontrolled hypertension); * Declared ocular disease, other than dry eye disease, with a significant impact on vision, such as visual field loss (e.g., glaucoma), reduced visual acuity, significant visual impairment in dim or bright environments (e.g., retinitis pigmentosa), corneal surface abnormalities including ectatic disorders (keratoconus, pellucid marginal degeneration), or corneal dystrophies (e.g., Fuchs dystrophy); * Declared autoimmune connective tissue disease or other condition known to cause dry eye disease (e.g., rheumatoid arthritis, rosacea, Crohn's disease, systemic lupus erythematosus, Graves' disease, Stevens-Johnson syndrome); * Active ocular or systemic allergy, or active ocular inflammatory condition such as keratitis, uveitis, blepharitis, etc.; * Declared neurological disorders, including a history of epilepsy, sensorimotor coordination disorders, ocular migraine, vestibular disease, or cerebellar disorders (e.g., balance disorders, nystagmus); * Binocular vision disorders such as strabismus, suppression, diplopia, amblyopia, or decompensated phorias associated with recurrent headaches, blurred or double vision, difficulty concentrating, or difficulties when frequently shifting focus between near and distance vision; * History of ocular surgery, refractive surgery, or ocular trauma; * Use of extended-wear contact lenses, rigid contact lenses, and/or orthokeratology lenses; * Prolonged wear of soft contact lenses (\>12 hours per day); * Use of medications that may influence vision or interfere with study assessments (e.g., antidepressants, tranquilizers, antipsychotics, oral retinoids, or medications with atropinic effects); * Ophthalmic treatments, light therapy, or other treatments for dry eye disease within the past 3 months, with the exception of over-the-counter eye drops not requiring a prescription, such as hyaluronic acid-based lubricants.